Biologic ustekinumab (Stelara) was approved in 2013 for the treatment of moderate to severe psoriatic arthritis in adult patients. It was first approved in 2009 for psoriasis. Ustekimumab can be used ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Celltrion’s Steqeyma, a biosimilar that references Johnson & Johnson’s blockbuster monoclonal antibody Stelara ... can treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Stelara (ustekinumab) was launched almost 15 years ago as a treatment for psoriasis and in the interim has picked up additional indications in psoriatic arthritis, Crohn’s disease, and ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Stelara (ustekinumab ... But thanks to advances in PsA treatments, most disease complications can be avoided. Juvenile psoriatic arthritis is a type of juvenile idiopathic arthritis.

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse cardiovascular and venous thromboembolic events compared with those treated ...